Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 10/20 | 0.32 |
| ▸ | FPR3 | P25089 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30797547 | 0.87 | ATR (0.42) | ATRKRASBRD4FPR3FPR2 | |
| SCHEMBL30797857 | 0.85 | ATR (0.41) | ATRKRASBRD4FPR3FPR2 | |
| SCHEMBL30797714 | 0.84 | ATR (0.41) | ATRKRASBRD4FPR3FPR2 | |
| SCHEMBL27377150 | 0.84 | ATR (0.41) | ATRKRASBRD4FPR3FPR2 | |
| SCHEMBL30797611 | 0.83 | ATR (0.47) | ATRRXRARXRBRXRG | |
| SCHEMBL30869074 | 0.83 | ATR (0.43) | ATRBRD4FPR3FPR2RXRA | |
| SCHEMBL30797730 | 0.83 | ATR (0.44) | ATRBRD4FPR3FPR2RXRA | |
| SCHEMBL30797974 | 0.83 | ATR (0.44) | ATRKRASBRD4FPR3FPR2 | |
| SCHEMBL30797688 | 0.83 | ATR (0.44) | ATRKRASBRD4FPR3FPR2 | |
| SCHEMBL30797751 | 0.82 | BRD4 (0.46) | ATRKRASBRD4FPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584249-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584266-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052701-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052701-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052702-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |